1. A pharmacology student asks why ACE inhibitors produce both a reduction in angiotensin II and an elevation in bradykinin simultaneously. Which of the following correctly explains the mechanistic basis for both effects?
A) ACE inhibitors block the AT1 receptor (angiotensin type 1 receptor), preventing angiotensin II from binding its effector receptor; the resulting accumulation of unbound angiotensin II is then shunted toward bradykinin synthesis via the kallikrein-kinin system, raising bradykinin levels as a secondary consequence of receptor-level RAAS blockade
B) ACE inhibitors suppress renin secretion from the juxtaglomerular apparatus through a direct tubuloglomerular feedback mechanism; reduced renin activity decreases angiotensin I generation, and the resulting reduction in ACE substrate availability paradoxically increases the enzyme's affinity for bradykinin, accelerating bradykinin degradation rather than causing accumulation
C) ACE inhibitors inhibit neprilysin (neutral endopeptidase), the enzyme responsible for degrading both angiotensin II and bradykinin; neprilysin inhibition simultaneously reduces angiotensin II degradation products (raising Ang II substrate for AT1 binding) and impairs bradykinin inactivation, producing the dual hemodynamic profile characteristic of ACEi therapy
D) Angiotensin-converting enzyme serves two distinct substrate functions: it converts angiotensin I to angiotensin II, and it degrades bradykinin into inactive fragments; ACE inhibitors block both functions simultaneously — reducing angiotensin II generation and impairing bradykinin degradation, raising bradykinin levels through the same enzymatic inhibition that reduces Ang II
E) ACE inhibitors activate the angiotensin-(1-7) pathway by diverting angiotensin I away from ACE-mediated conversion toward ACE2-mediated cleavage; angiotensin-(1-7) then stimulates the Mas receptor, which upregulates bradykinin synthesis in vascular endothelium — thereby producing vasodilation through both reduced Ang II and elevated bradykinin via mechanistically distinct pathways
ANSWER: D
Rationale:
Option D is correct. Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxypeptidase with two distinct physiological substrate functions: it cleaves the decapeptide angiotensin I to generate the octapeptide angiotensin II, and it inactivates bradykinin — a vasodilatory kinin peptide — by cleaving its C-terminal dipeptides. ACE inhibitors competitively inhibit this single enzyme and therefore simultaneously suppress both functions: angiotensin II generation falls (reducing vasoconstriction, aldosterone release, sympathetic activation, and maladaptive cardiac remodeling), and bradykinin degradation is impaired (raising bradykinin levels and amplifying vasodilation, natriuresis, and endothelial nitric oxide release). Both effects arise from inhibition of the same enzyme acting on two different substrates — not from two mechanistically separate drug actions.
Option A: Option A is incorrect; ACE inhibitors do not act at the AT1 receptor — that is the mechanism of ARBs; ACEi act upstream at the converting enzyme; angiotensin II is not shunted toward bradykinin synthesis when AT1 receptors are blocked.
Option B: Option B is incorrect; ACE inhibitors cause reactive hyperreninemia — reduced angiotensin II negative feedback increases, not decreases, renin secretion; additionally, reduced ACE substrate availability does not increase the enzyme's affinity for bradykinin — it is the enzyme's inhibition that impairs bradykinin degradation.
Option C: Option C is incorrect; ACE inhibitors do not inhibit neprilysin — neprilysin inhibition is the mechanism of sacubitril; the two enzyme systems are distinct; ACEi do not affect neprilysin activity.
Option E: Option E is incorrect; while ACE inhibition does allow more angiotensin I to be processed by ACE2 toward angiotensin-(1-7), this is not the primary mechanism of bradykinin elevation on ACEi therapy; bradykinin elevation results directly from impaired ACE-mediated bradykinin degradation, not from Mas receptor-mediated bradykinin upregulation.
2. A 68-year-old man with HFrEF developed dry cough on lisinopril and is switched to valsartan. His cardiologist explains that valsartan will not cause cough. Which of the following most precisely explains why ARBs (angiotensin receptor blockers) are free of the cough that characterizes ACEi therapy?
A) ARBs inhibit neprilysin at a distinct active site from sacubitril, producing partial bradykinin degradation that prevents accumulation sufficient to stimulate bronchial C-fiber afferents; the partial degradation is enough to maintain bradykinin below the cough-reflex threshold while still amplifying natriuretic peptide levels
B) ARBs block the AT1 receptor downstream of ACE and do not inhibit angiotensin-converting enzyme; because ACE remains fully active, bradykinin degradation proceeds at its normal rate and bradykinin does not accumulate in the airways; since ACEi-induced cough results specifically from bradykinin accumulation due to impaired ACE-mediated bradykinin degradation, and this mechanism is absent with ARBs, cough is not a class effect of ARB therapy
C) ARBs block both AT1 and AT2 receptors; AT2 receptor blockade in the bronchial mucosa directly prevents bradykinin-mediated C-fiber sensitization by competitively occupying the bradykinin B2 receptor binding domain, thereby raising the cough reflex threshold without altering circulating bradykinin levels
D) ARBs suppress renin secretion through direct feedback at the juxtaglomerular apparatus, reducing angiotensin I generation and leaving less substrate for ACE-mediated bradykinin generation; reduced bradykinin synthesis — rather than preserved degradation — explains the absence of cough with ARB therapy
E) ARBs cause compensatory upregulation of ACE expression at the vascular endothelial level through an AT1-mediated genomic feedback mechanism; increased ACE expression accelerates bradykinin degradation above baseline, actively suppressing bradykinin below the level present without any RAAS-blocking therapy
ANSWER: B
Rationale:
Option B is correct. ARBs selectively block the AT1 receptor — the primary effector receptor through which angiotensin II exerts its vasoconstrictor, pro-fibrotic, and aldosterone-stimulating effects. ARBs do not interact with angiotensin-converting enzyme in any way. Because ACE remains fully active, its bradykinin-degrading function is unimpaired: bradykinin continues to be metabolized at its normal rate and does not accumulate in the bronchial mucosa. ACEi-induced cough arises specifically because ACE inhibition impairs bradykinin degradation, allowing bradykinin to accumulate and sensitize bronchial sensory C-fiber afferents. Since ARBs leave ACE uninhibited, this mechanism is entirely absent — cough incidence with ARBs is comparable to placebo and is not a class effect. This mechanistic distinction is clinically actionable: switching from an ACEi to an ARB reliably resolves ACEi-induced cough.
Option A: Option A is incorrect; ARBs do not inhibit neprilysin at any site; neprilysin inhibition is the mechanism of sacubitril; ARBs have no effect on bradykinin degradation through any enzymatic pathway.
Option C: Option C is incorrect; ARBs selectively block the AT1 receptor and do not block AT2 receptors; the AT2 receptor is not a bradykinin B2 receptor and ARBs do not occupy the bradykinin B2 receptor binding domain; this mechanism is pharmacologically fabricated.
Option D: Option D is incorrect; ARBs cause reactive hyperreninemia — by blocking AT1-mediated feedback, Ang II cannot suppress renin release, so renin increases rather than decreases; furthermore, bradykinin is generated by the kallikrein-kinin system, not as a product of ACE acting on angiotensin I.
Option E: Option E is incorrect; AT1 receptor blockade does not upregulate ACE expression through a genomic feedback mechanism that accelerates bradykinin degradation above baseline; ACE expression is not dynamically regulated in this manner by ARB therapy.
3. A resident asks why sacubitril — a neprilysin inhibitor — is always combined with valsartan in the fixed-dose tablet Entresto, rather than administered as a standalone neprilysin inhibitor in HFrEF. Which of the following best explains the pharmacodynamic necessity of combining sacubitril with an ARB?
A) Sacubitril alone causes clinically unacceptable hyperkalemia because neprilysin degrades aldosterone in the adrenal cortex; when neprilysin is inhibited, aldosterone accumulates and drives sodium retention and potassium reabsorption in the collecting duct; valsartan counteracts this by blocking AT1-mediated aldosterone release, restoring potassium balance
B) Sacubitril's active metabolite LBQ657 is rapidly cleared by renal tubular secretion via the OAT3 (organic anion transporter 3) pathway; valsartan competitively inhibits OAT3, slowing LBQ657 renal elimination and extending its pharmacodynamic half-life sufficiently to maintain neprilysin inhibition throughout the dosing interval
C) Sacubitril alone produces excessive accumulation of natriuretic peptides that overwhelms NPR-A receptor (natriuretic peptide receptor A) capacity, causing paradoxical receptor downregulation; valsartan prevents this desensitization by blocking AT1-mediated NPR-A internalization, preserving long-term responsiveness to elevated natriuretic peptide levels
D) Sacubitril alone would produce dangerous bradycardia through excessive natriuretic peptide-mediated suppression of sinoatrial node automaticity; valsartan attenuates natriuretic peptide signaling at the NPR-A receptor, reducing chronotropic suppression to a clinically safe level while preserving vasodilatory and natriuretic benefits
E) Neprilysin degrades multiple vasoactive substrates including natriuretic peptides and angiotensin II; inhibiting neprilysin raises natriuretic peptides beneficially but also impairs angiotensin II degradation, raising Ang II levels and risking maladaptive vasoconstriction, aldosterone release, and cardiac remodeling; the valsartan component blocks the AT1 receptor, neutralizing the elevated Ang II and ensuring the net pharmacodynamic result of neprilysin inhibition is beneficial rather than counterproductive
ANSWER: E
Rationale:
Option E is correct. Neprilysin is a promiscuous zinc metallopeptidase that degrades a broad range of vasoactive peptides. While its therapeutically targeted substrates are the natriuretic peptides — ANP (atrial natriuretic peptide), BNP (B-type natriuretic peptide), and CNP (C-type natriuretic peptide) — neprilysin also degrades angiotensin II. When sacubitril inhibits neprilysin, angiotensin II degradation is impaired along with natriuretic peptide degradation. The resulting rise in Ang II levels would drive the very maladaptive neurohormonal activation — vasoconstriction, aldosterone secretion, sympathetic potentiation, and pathological cardiac fibrosis — that RAAS-directed HF therapy aims to suppress. A standalone neprilysin inhibitor would therefore produce a pharmacodynamically self-defeating result: raising beneficial counter-regulatory peptides while simultaneously raising the primary maladaptive driver of HFrEF progression. The valsartan component resolves this by blocking the AT1 receptor, preventing the elevated Ang II from exerting its harmful effects. This is why the ARNI design pairs neprilysin inhibition with AT1 receptor blockade rather than with ACE inhibition — the earlier omapatrilat (ACEi + neprilysin inhibitor) combination produced dangerous angioedema from combined bradykinin accumulation.
Option A: Option A is incorrect; neprilysin does not degrade aldosterone in the adrenal cortex as a clinically significant pathway; hyperkalemia is not the primary risk from standalone neprilysin inhibition; the rationale for valsartan is Ang II accumulation, not aldosterone-mediated potassium dysregulation.
Option B: Option B is incorrect; the necessity of the sacubitril/valsartan combination is pharmacodynamic, not pharmacokinetic; OAT3-mediated LBQ657 tubular secretion is not the reason for the fixed combination; valsartan does not function as an OAT3 inhibitor to extend sacubitril exposure.
Option C: Option C is incorrect; natriuretic peptide receptor downregulation from NPR-A overload is not an established mechanism of clinical significance with sacubitril therapy; AT1-mediated NPR-A internalization that valsartan would prevent is pharmacologically fabricated.
Option D: Option D is incorrect; natriuretic peptides do not suppress sinoatrial node automaticity to a clinically significant degree at therapeutic concentrations; bradycardia is not a recognized adverse effect of neprilysin inhibition at therapeutic doses, and valsartan is not included to attenuate chronotropic NPR-A effects.
4. A 72-year-old woman with HFrEF on sacubitril/valsartan presents with 3 weeks of worsening dyspnea and 5 kg weight gain. Her BNP (B-type natriuretic peptide) returns at 220 pg/mL. The intern considers this only mildly elevated and not indicative of significant decompensation. Which of the following best identifies the error in this reasoning and the correct biomarker approach?
A) The intern's reasoning is incorrect because BNP is an unreliable biomarker in patients receiving sacubitril/valsartan; sacubitril inhibits neprilysin, the primary enzyme responsible for degrading BNP in the circulation, causing BNP to accumulate artifactually independent of true ventricular filling pressure; NT-proBNP (N-terminal pro-BNP), which is not a neprilysin substrate, remains accurate in patients on sacubitril/valsartan and should be used to assess HF severity and congestion in this population
B) The intern is correct that BNP of 220 pg/mL is only mildly elevated; however, the correct response is to repeat BNP in 48 hours after empirically doubling the furosemide dose; if the repeat BNP does not fall by at least 30%, invasive hemodynamic assessment with right heart catheterization is warranted to distinguish cardiac from non-cardiac causes of dyspnea
C) The intern's reasoning is incorrect because BNP is unreliable in patients on sacubitril/valsartan due to valsartan-mediated competitive inhibition of the BNP immunoassay antibody at the C-terminal BNP epitope; the correct biomarker is NT-proBNP, which uses a different antibody target unaffected by valsartan; BNP should never be ordered in patients on any ARB-containing regimen
D) The intern is correct that BNP of 220 pg/mL reflects adequate neurohormonal control in an optimally treated HFrEF patient; sacubitril/valsartan reduces ventricular wall stress so effectively that BNP synthesis is genuinely suppressed to near-normal levels; the worsening dyspnea and weight gain are likely non-cardiac and should prompt pulmonary evaluation before adjusting heart failure medications
E) The intern's reasoning is incorrect because BNP above 100 pg/mL always indicates hemodynamic decompensation regardless of the treatment regimen; a BNP of 220 pg/mL in a patient with worsening dyspnea and weight gain confirms acute decompensated HFrEF requiring hospital admission and intravenous diuresis regardless of other clinical factors
ANSWER: A
Rationale:
Option A is correct. BNP is a substrate for neprilysin — the enzyme inhibited by the sacubitril component of sacubitril/valsartan. When neprilysin is inhibited, BNP degradation in the circulation is impaired, causing BNP to accumulate independent of true changes in ventricular wall stress or filling pressures. This renders BNP uninterpretable as a marker of HF severity in patients on sacubitril/valsartan — a value that appears "only mildly elevated" may reflect artifactual accumulation from impaired degradation rather than genuine neurohormonal control, and cannot be used to reassure the clinician that decompensation is not occurring. NT-proBNP (N-terminal pro-BNP) is the inactive N-terminal cleavage product of the BNP prohormone; it is not a neprilysin substrate and its clearance is unaffected by sacubitril, making it the reliable biomarker for assessing congestion and HF severity in patients on ARNI therapy. The clinical picture here — 3 weeks of worsening dyspnea and 5 kg weight gain — together with an uninterpretable BNP demands NT-proBNP measurement and direct volume status assessment rather than false reassurance from an invalid biomarker.
Option B: Option B is incorrect; before empirically escalating diuretics, the first step is to obtain a valid biomarker (NT-proBNP) and perform direct clinical volume status assessment; empirical diuretic doubling based on an uninterpretable BNP value in a patient with concerning clinical features risks both under- and over-treatment.
Option C: Option C is incorrect; the BNP assay interference is not caused by valsartan competitively inhibiting immunoassay antibody binding — there is no structural homology between valsartan and BNP that causes such interference; BNP unreliability is specific to neprilysin inhibition by sacubitril, not to the ARB component; BNP can be ordered in patients on standalone ARB therapy without this concern.
Option D: Option D is incorrect; while sacubitril/valsartan does reduce neurohormonal activation over time, the primary reason BNP is unreliable is impaired enzymatic degradation from neprilysin inhibition, not genuine wall stress normalization; dismissing 5 kg weight gain and worsening dyspnea as non-cardiac based on a BNP value that is pharmacologically uninterpretable would be clinically dangerous.
Option E: Option E is incorrect; BNP thresholds for decompensation cannot be applied categorically in patients on sacubitril/valsartan because the values are artifactually elevated by neprilysin inhibition; the cutoff of 100 pg/mL applies to patients not on neprilysin inhibitors; in patients on sacubitril/valsartan, NT-proBNP is the appropriate biomarker and its absolute thresholds differ from BNP thresholds.
5. A cardiologist is transitioning a patient from ramipril to sacubitril/valsartan. A second patient is being transitioned from irbesartan to sacubitril/valsartan. Which of the following correctly describes the required washout for each transition and the mechanistic reason for the difference?
A) Both transitions require a 36-hour washout; the interval is universally required before any change in RAAS-modifying therapy to prevent rebound neurohormonal activation from abrupt RAAS-level discontinuation, regardless of the specific agents involved
B) Ramipril transition: no washout required because ramipril has a short plasma half-life and is fully cleared within 6 hours; sacubitril/valsartan can be started on the same day ramipril is stopped. Irbesartan transition: 36-hour washout required because irbesartan's prolonged AT1 receptor occupancy potentiates the hypotensive effect of the valsartan component in sacubitril/valsartan for up to 48 hours
C) Ramipril transition: stop ramipril and wait 36 hours before initiating sacubitril/valsartan; concurrent ACE inhibition and neprilysin inhibition each independently impair bradykinin degradation, and additive bradykinin accumulation raises angioedema risk to an unacceptable level. Irbesartan transition: no washout required; ARBs do not inhibit ACE or neprilysin and do not raise bradykinin, so there is no pharmacodynamic bradykinin accumulation risk to carry into sacubitril/valsartan initiation
D) Ramipril transition: taper over 2 weeks halving the dose every 3–4 days, then start sacubitril/valsartan immediately after the last dose; abrupt ACEi discontinuation risks rebound neurohormonal activation and acute decompensation. Irbesartan transition: 36-hour washout required to allow full AT1 receptor dissociation before the valsartan component of sacubitril/valsartan occupies the same receptor
E) Ramipril transition: 36-hour washout required. Irbesartan transition: 72-hour washout required because irbesartan is a non-competitive (insurmountable) AT1 receptor antagonist whose prolonged receptor dissociation half-life, combined with the valsartan component of sacubitril/valsartan, risks additive complete AT1 receptor blockade producing severe hypotension for up to 3 days
ANSWER: C
Rationale:
Option C is correct. The ACEi-to-ARNI transition requires a mandatory 36-hour washout because ACE inhibitors and sacubitril both independently impair bradykinin degradation through distinct enzymatic pathways: ACEi inhibit ACE-mediated bradykinin inactivation, while sacubitril inhibits neprilysin-mediated bradykinin inactivation. Simultaneous inhibition of both pathways produces additive bradykinin accumulation that can cause potentially fatal laryngeal angioedema. The 36-hour washout allows sufficient recovery of ACE activity before neprilysin inhibition is initiated. For the ARB-to-ARNI transition, no washout is required: ARBs block the AT1 receptor without inhibiting ACE or neprilysin, so bradykinin degradation proceeds normally throughout ARB therapy; there is no carry-over bradykinin accumulation risk when sacubitril/valsartan is started. Irbesartan is discontinued on the day sacubitril/valsartan is initiated.
Option A: Option A is incorrect; a universal 36-hour washout for all RAAS transitions is not guideline-endorsed; the ARB-to-ARNI transition specifically requires no washout; the concern driving the ACEi washout is angioedema from additive bradykinin accumulation, not rebound neurohormonal activation from abrupt discontinuation.
Option B: Option B is incorrect; ramipril does not have a plasma half-life of 6 hours permitting same-day initiation; ramiprilat (the active diacid metabolite) has a prolonged effective pharmacodynamic half-life with tissue ACE inhibition persisting well beyond plasma clearance; the 36-hour washout is based on pharmacodynamic ACE activity recovery, not plasma pharmacokinetics; irbesartan does not require a 36-hour washout.
Option D: Option D is incorrect; no gradual taper of the ACEi is required before transitioning to sacubitril/valsartan; the correct protocol is abrupt cessation followed by the 36-hour washout; additionally, irbesartan does not require a washout for receptor dissociation reasons — ARBs are competitive (surmountable) AT1 antagonists and the valsartan component of sacubitril/valsartan simply occupies the same receptor without any risk from prior irbesartan use.
Option E: Option E is incorrect; irbesartan, while considered a high-affinity AT1 antagonist, does not require a 72-hour washout before sacubitril/valsartan; competitive AT1 displacement by valsartan does not produce additive complete blockade causing dangerous hypotension; there is no pharmacological basis for this 72-hour requirement.
6. Which of the following most accurately summarizes the primary outcome, active comparator, and key design feature of PARADIGM-HF?
A) PARADIGM-HF randomized 8,442 patients with HFrEF (LVEF ≤40%, NYHA class II–IV) to sacubitril/valsartan versus placebo added to background enalapril; sacubitril/valsartan reduced the primary composite of cardiovascular death or HF hospitalization by 20%; no run-in period was used, and the result reflects the benefit of ARNI in a broad unselected HFrEF population
B) PARADIGM-HF randomized 3,164 patients with HFrEF to sacubitril/valsartan versus enalapril; the primary endpoint of all-cause mortality was reduced by 20% (HR 0.80); the trial was stopped early at a pre-planned interim analysis after crossing the alpha-spending boundary, and a mandatory run-in period pre-selected patients tolerant of both agents
C) PARADIGM-HF demonstrated that sacubitril/valsartan reduced HF hospitalization but did not reach statistical significance for cardiovascular mortality as an independent endpoint; FDA approval was granted on the composite endpoint alone, with a label statement that the mortality benefit was driven entirely by the hospitalization component
D) PARADIGM-HF randomized 8,442 patients with HFrEF (LVEF ≤40%, NYHA class II–IV) to sacubitril/valsartan versus enalapril; sacubitril/valsartan reduced the primary composite of cardiovascular death or HF hospitalization by 20% (HR 0.80; p<0.001), reduced all-cause mortality by 16%, cardiovascular mortality by 20%, and sudden cardiac death by 20%; the trial was stopped early for overwhelming efficacy, and a mandatory sequential run-in period selected patients tolerant of both agents before randomization
E) PARADIGM-HF compared sacubitril/valsartan to valsartan alone in 8,442 patients with HFrEF, demonstrating that the addition of sacubitril's neprilysin inhibition to AT1 receptor blockade reduced the primary composite by 20%; this design confirmed that the mortality benefit is attributable to the sacubitril component rather than the shared valsartan component
ANSWER: D
Rationale:
Option D is correct. PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) enrolled 8,442 patients with chronic HFrEF (LVEF ≤40%, NYHA class II–IV, with elevated natriuretic peptides) and randomized them to sacubitril/valsartan 97/103 mg twice daily or enalapril 10 mg twice daily. The primary composite endpoint — cardiovascular death or first HF hospitalization — was reduced by 20% (HR 0.80; 95% CI 0.73–0.87; p<0.001). Key secondary endpoints were all reduced significantly: all-cause mortality by 16%, cardiovascular mortality by 20%, HF hospitalization by 21%, and sudden cardiac death by 20%. The trial was stopped early by the data safety monitoring board for overwhelming efficacy. A critical design feature was the mandatory sequential run-in period: patients first tolerated enalapril alone, then sacubitril/valsartan alone, before randomization — pre-selecting a tolerability-enriched population and likely underestimating the absolute benefit in unselected real-world patients.
Option A: Option A is incorrect; PARADIGM-HF compared sacubitril/valsartan directly to enalapril as the active comparator — not to placebo on background enalapril; combining ARNI with ACEi is contraindicated; a run-in period was used and is a key design feature of the trial.
Option B: Option B is incorrect; PARADIGM-HF enrolled 8,442 patients, not 3,164 (ATLAS enrolled approximately 3,164); the primary endpoint was cardiovascular death or HF hospitalization (a composite), not all-cause mortality alone; all-cause mortality was reduced by 16%, not 20%.
Option C: Option C is incorrect; PARADIGM-HF demonstrated statistically significant reductions in cardiovascular mortality as an independent endpoint; there is no FDA label statement attributing the mortality benefit solely to the hospitalization component; this characterization is factually incorrect.
Option E: Option E is incorrect; PARADIGM-HF compared sacubitril/valsartan to enalapril — not to valsartan alone; this design tested ARNI versus standard-of-care ACEi, not ARNI versus its ARB component alone; a valsartan comparator arm was not included in PARADIGM-HF.
7. A hospitalist asks which trial specifically established that sacubitril/valsartan can be safely initiated in-hospital in patients stabilized after acute decompensated HFrEF, and what it demonstrated. Which of the following is correct?
A) STRONG-HF established in-hospital ARNI safety by randomizing stabilized patients to sacubitril/valsartan or enalapril within 24 hours of admission; sacubitril/valsartan reduced in-hospital mortality by 42% and established same-day ARNI initiation at presentation as standard of care for acute decompensated HFrEF
B) PIONEER-HF randomized 881 patients hospitalized for acute decompensated HFrEF to in-hospital initiation of sacubitril/valsartan versus enalapril after meeting hemodynamic stabilization criteria; sacubitril/valsartan produced a significantly greater reduction in NT-proBNP at 8 weeks (46.7% vs. 25.3%) with no significant difference in rates of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema — establishing that in-hospital ARNI initiation in hemodynamically stable patients is safe and accelerates neurohormonal decongestion
C) PARADIGM-HF included a pre-specified subgroup of patients enrolled within 72 hours of hospitalization for acute decompensated HFrEF; this subgroup demonstrated a 35% reduction in 30-day readmission with in-hospital sacubitril/valsartan initiation, providing the prospective evidence base for in-hospital ARNI initiation reflected in current guidelines
D) No prospective randomized trial has specifically examined in-hospital ARNI initiation; guideline support for in-hospital sacubitril/valsartan is derived entirely from post-hoc analyses of PARADIGM-HF and observational data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry
E) ATMOSPHERE demonstrated that in-hospital sacubitril/valsartan initiation within 48 hours of admission for acute decompensated HFrEF was associated with a significant increase in worsening renal function (18% vs. 6%) and was terminated early for safety; current guidelines therefore recommend deferring ARNI initiation until at least 2 weeks after discharge and clinical stabilization
ANSWER: B
Rationale:
Option B is correct. PIONEER-HF (Comparison of Sacubitril/Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) was specifically designed to address in-hospital ARNI initiation. It enrolled 881 patients hospitalized for acute decompensated HFrEF (LVEF ≤40%) who had achieved hemodynamic stabilization — defined as SBP ≥100 mmHg, no IV vasodilators or inotropes for ≥6 hours, no IV diuretics for ≥6 hours, and appropriate volume status. Patients were randomized in-hospital to sacubitril/valsartan or enalapril prior to discharge. The primary endpoint — time-averaged proportional change in NT-proBNP from baseline through weeks 4 and 8 — showed a significantly greater reduction with sacubitril/valsartan (46.7% vs. 25.3%; ratio of change 0.71, 95% CI 0.63–0.81). Critically, there were no significant differences in rates of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema between arms — establishing safety of in-hospital initiation in stabilized patients and supporting earlier rather than deferred ARNI initiation.
Option A: Option A is incorrect; STRONG-HF studied the strategy of high-intensity versus usual-care GDMT optimization in recently hospitalized patients but did not directly compare sacubitril/valsartan to enalapril, and did not report a 42% in-hospital mortality reduction; PIONEER-HF — not STRONG-HF — is the trial that established in-hospital ARNI safety.
Option C: Option C is incorrect; PARADIGM-HF enrolled outpatients with chronic stable HFrEF, not acutely hospitalized patients, and did not include a pre-specified in-hospital initiation subgroup; PIONEER-HF is the prospective randomized evidence source for in-hospital initiation.
Option D: Option D is incorrect; PIONEER-HF is a prospective randomized controlled trial that directly and specifically examined in-hospital initiation; the statement that no such trial exists is factually wrong.
Option E: Option E is incorrect; no trial called ATMOSPHERE demonstrated that in-hospital ARNI initiation caused increased renal dysfunction leading to early termination; PIONEER-HF demonstrated the opposite — in-hospital initiation after hemodynamic stabilization was safe; this trial description is fabricated.
8. A cardiology fellow argues that combining an ACEi with an ARB would provide additive RAAS suppression and superior outcomes in HFrEF. Which of the following best explains why current guidelines advise against this combination?
A) The ONTARGET trial demonstrated that combining ramipril with telmisartan in high-cardiovascular-risk patients significantly increased rates of hypotension, acute kidney injury, doubling of serum creatinine, and dialysis initiation without reducing the primary composite of cardiovascular death, MI, stroke, or HF hospitalization compared to either agent alone; current 2022 AHA/ACC/HFSA guidelines do not recommend routine dual ACEi plus ARB therapy in HFrEF, and the combination is specifically contraindicated when an MRA (mineralocorticoid receptor antagonist) is already present in the regimen
B) The CHARM-Added trial demonstrated that candesartan added to background ACEi significantly increased all-cause mortality compared to ACEi alone due to excessive neurohormonal suppression causing hemodynamic collapse; the 2022 AHA/ACC/HFSA guidelines therefore give dual ACEi plus ARB therapy a Class III (harm) recommendation in all HFrEF patients regardless of concurrent medications
C) Dual ACEi plus ARB therapy is contraindicated exclusively due to the risk of severe hyperkalemia from combined aldosterone suppression; the combination is acceptable in patients with well-controlled potassium (K⁺ <4.5 mEq/L) and eGFR above 60 mL/min/1.73m², with monthly electrolyte monitoring, and carries a Class IIb (weak positive) recommendation in carefully selected patients
D) Dual ACEi plus ARB therapy is no longer recommended because sacubitril/valsartan has superseded it; the combination is not actively contraindicated but is simply deprioritized in favor of ARNI therapy; in patients who cannot access sacubitril/valsartan, ACEi plus ARB remains an acceptable fallback per the 2022 AHA/ACC/HFSA guidelines
E) Dual ACEi plus ARB therapy is contraindicated because ARBs competitively displace ACEi molecules from the ACE active site, reducing ACE inhibition below the therapeutic threshold needed for meaningful angiotensin II suppression; the net result is inadequate RAAS blockade despite two drugs, and the pharmacodynamic antagonism between ACEi and ARB at the enzyme level makes the combination pharmacologically self-defeating
ANSWER: A
Rationale:
Option A is correct. The ONTARGET trial enrolled patients at high cardiovascular risk and compared ramipril alone, telmisartan alone, or the combination. The dual therapy arm demonstrated significantly increased rates of hypotension, acute kidney injury, doubling of serum creatinine, and initiation of dialysis compared to either agent alone — without any reduction in the primary composite of cardiovascular death, myocardial infarction, stroke, or HF hospitalization. This adverse renal and hemodynamic signal without survival benefit shifted the risk-benefit analysis decisively against routine dual RAAS blockade. While CHARM-Added did demonstrate reduced HF hospitalization with candesartan added to ACEi, the ONTARGET renal harm data preclude a positive guideline recommendation for the combination. The combination is additionally and specifically contraindicated when an MRA (spironolactone or eplerenone) is already in the regimen — the triple combination of ACEi + ARB + MRA produces unacceptable rates of hyperkalemia and renal deterioration.
Option B: Option B is incorrect; CHARM-Added did not demonstrate that candesartan increased all-cause mortality — it showed a reduction in HF hospitalization with the combination; the 2022 AHA/ACC/HFSA guidelines do not give dual ACEi plus ARB a Class III (harm) recommendation as universally harmful; the recommendation is against routine use based on the ONTARGET renal harm data, not based on demonstrated excess mortality.
Option C: Option C is incorrect; the contraindication to dual ACEi plus ARB is not limited to hyperkalemia risk; the ONTARGET data showed renal harm as the predominant adverse signal even in patients without significant hyperkalemia at baseline; the combination does not carry a Class IIb positive recommendation in any selected subpopulation in current guidelines.
Option D: Option D is incorrect; ACEi plus ARB is not merely deprioritized — it is actively not recommended due to demonstrated renal harm; it is not an acceptable fallback for patients who cannot access sacubitril/valsartan; an ACEi alone or ARB alone (not combined) remains the appropriate alternative when ARNI is unavailable.
Option E: Option E is incorrect; ARBs do not bind to ACE or competitively displace ACEi from the ACE active site; ARBs act exclusively at the angiotensin II AT1 receptor, which is downstream of and entirely distinct from ACE; there is no pharmacodynamic antagonism between ACEi and ARB at the enzyme level.
9. A 64-year-old woman with HFrEF on enalapril develops sudden tongue and lip swelling without urticaria 6 weeks after starting the drug. The reaction resolves over 12 hours with supportive care. Which of the following correctly describes the mechanism of this reaction and its implications for future RAAS therapy selection?
A) This represents an IgE-mediated type I hypersensitivity reaction to enalapril; cross-reactivity among ACEi is low, so switching to a structurally dissimilar ACEi such as lisinopril is appropriate; sacubitril/valsartan is contraindicated due to its ARB component but an ACEi rechallenge is safe with premedication using antihistamines and corticosteroids
B) This represents ACEi angioedema caused by angiotensin II accumulation at AT2 receptors in submucosal tissue; switching to sacubitril/valsartan is appropriate because the valsartan component provides AT2 receptor blockade, preventing the submucosal edema mechanism; ARBs are insufficient because they block only AT1 receptors
C) This represents ACEi angioedema caused by bradykinin accumulation; because the reaction occurred within 6 weeks of initiation, it represents an early-onset pharmacokinetic accumulation phenomenon; reducing the enalapril dose to the lowest effective level and rechallenging after a 4-week washout is a reasonable approach before committing to drug class change
D) This represents ACEi angioedema caused by bradykinin accumulation; the absence of urticaria distinguishes this from IgE-mediated allergic angioedema; switching to a different ACEi is safe because ACEi angioedema is agent-specific rather than a class effect, and angioedema to enalapril specifically does not predict angioedema to lisinopril or ramipril
E) This represents ACEi-induced angioedema caused by bradykinin accumulation — ACE inhibition impairs bradykinin degradation, producing submucosal edema without urticaria; this is an absolute contraindication to rechallenge with any ACEi and to sacubitril/valsartan (which independently raises bradykinin through neprilysin inhibition); an ARB is the appropriate RAAS-blocking alternative, as ARBs do not inhibit ACE or neprilysin and do not raise bradykinin
ANSWER: E
Rationale:
Option E is correct. ACEi-induced angioedema is caused by bradykinin accumulation: ACE inhibition impairs bradykinin degradation, and elevated bradykinin increases vascular permeability in submucosal tissues, producing the characteristic tongue, lip, and oropharyngeal swelling. Unlike IgE-mediated allergic angioedema, ACEi angioedema is not associated with urticaria — its absence in this patient is consistent with, not against, the diagnosis. This is a class effect of all ACEi — any ACEi raises bradykinin through the same mechanism, and rechallenge with any agent in the class is absolutely contraindicated. Sacubitril/valsartan is similarly contraindicated because the sacubitril component inhibits neprilysin, a second independent bradykinin-degrading enzyme; in a patient sensitized by prior ACEi angioedema, additive bradykinin accumulation from neprilysin inhibition risks potentially fatal laryngeal angioedema. The correct RAAS-blocking alternative is an ARB: ARBs block the AT1 receptor without inhibiting ACE or neprilysin, do not raise bradykinin, and are safe and guideline-endorsed in patients with prior ACEi angioedema.
Option A: Option A is incorrect; ACEi angioedema is not IgE-mediated — it is a pharmacodynamic bradykinin-mediated reaction that is a class effect of all ACEi; switching to a different ACEi is not safe; antihistamine and corticosteroid premedication does not mitigate bradykinin-mediated angioedema; sacubitril/valsartan is contraindicated due to the sacubitril (neprilysin inhibitor) component, not the ARB component.
Option B: Option B is incorrect; ACEi angioedema is caused by bradykinin accumulation, not angiotensin II at AT2 receptors; valsartan blocks AT1 receptors, not AT2 receptors; sacubitril/valsartan is contraindicated in patients with prior ACEi angioedema, not recommended as an appropriate switch.
Option C: Option C is incorrect; ACEi angioedema is not a pharmacokinetic accumulation phenomenon limited to the early initiation period — it can occur at any time during therapy, including months to years after starting the drug; dose reduction and rechallenge are not appropriate management; the reaction is a class effect and the drug must be permanently discontinued.
Option D: Option D is incorrect; ACEi angioedema is a class effect of all ACEi — it is not agent-specific; angioedema on enalapril is a contraindication to all ACEi including lisinopril and ramipril; switching to a different ACEi in this patient risks recurrent and potentially more severe angioedema.
10. A 70-year-old man with HFrEF (LVEF 28%) and stage 3b CKD (eGFR 31 mL/min/1.73m²) is admitted for acute decompensated HF. After stabilization, his intern recommends withholding RAAS blockade indefinitely given the reduced eGFR. Which of the following best reflects the correct approach to RAAS blockade in this patient?
A) RAAS blockade is contraindicated in all patients with HFrEF and eGFR below 45 mL/min/1.73m²; hydralazine/isosorbide dinitrate is the guideline-recommended RAAS-sparing neurohormonal modifier in this population and should be initiated at the time of discharge
B) RAAS blockade should be initiated immediately at the time of acute decompensated HF presentation, regardless of hemodynamic status or volume overload, because the cardioprotective mortality benefit of RAAS blockade in HFrEF with CKD outweighs any acute renal risk and early initiation improves long-term outcomes
C) RAAS blockade is appropriate in patients with HFrEF and stable moderate CKD (eGFR approximately 20–60 mL/min/1.73m²) outside of acute illness; it should not be initiated during acute decompensation or AKI (acute kidney injury); a modest creatinine rise of up to 30% after initiation on a stable outpatient basis represents an expected hemodynamic effect rather than nephrotoxicity and is not an indication to withhold therapy; during intercurrent illness causing volume depletion, RAAS blockers should be temporarily held and restarted after recovery
D) RAAS blockade is safe to initiate in moderate CKD, but sacubitril/valsartan is specifically contraindicated at eGFR below 60 mL/min/1.73m²; an ACEi or ARB should be used until eGFR improves above this threshold, at which point transition to sacubitril/valsartan can be considered
E) RAAS blockade in HFrEF with CKD requires a nephrology consultation and 3-month specialist-supervised washout period before initiation to establish the patient's individual renal risk profile; the 2022 AHA/ACC/HFSA guidelines mandate this nephrology clearance step for all patients with eGFR below 60 mL/min/1.73m² before commencing any RAAS-blocking therapy
ANSWER: C
Rationale:
Option C is correct. RAAS blockade is appropriate in patients with HFrEF and stable moderate CKD (eGFR approximately 20–60 mL/min/1.73m²) and carries a Class I guideline recommendation — withholding survival-modifying therapy based on moderate CKD alone denies a meaningful mortality benefit. However, RAAS blockers should not be initiated during acute decompensation with hemodynamic instability, or during acute kidney injury, because reduced renal perfusion dramatically amplifies the risk of further renal deterioration. This patient should be stabilized and discharged, then started on RAAS therapy as an outpatient when clinically stable. A creatinine rise of up to approximately 30% above baseline after initiation on a stable basis is an expected hemodynamic effect — reduced intraglomerular pressure from efferent arteriolar dilation — and does not represent intrinsic nephrotoxicity or predict accelerated CKD progression. The sick day rule is equally important: during intercurrent illness causing volume depletion (gastroenteritis, febrile illness, excessive diuresis), RAAS blockers should be temporarily held to prevent AKI and restarted after recovery.
Option A: Option A is incorrect; there is no eGFR threshold of 45 mL/min/1.73m² constituting an absolute contraindication to RAAS blockade in HFrEF; hydralazine/isosorbide dinitrate is specifically indicated as additive therapy in self-identified Black patients with persistent NYHA III–IV symptoms, not as a RAAS-sparing universal alternative for CKD patients of any racial group.
Option B: Option B is incorrect; RAAS blockers should not be initiated during acute hemodynamic decompensation or AKI; initiating RAAS therapy while the patient is volume-overloaded, hemodynamically unstable, or experiencing acute renal hypoperfusion significantly increases the risk of AKI and worsening renal function; the correct approach is to stabilize first, then initiate as an outpatient.
Option D: Option D is incorrect; sacubitril/valsartan is not contraindicated at eGFR below 60 mL/min/1.73m²; it can be used at eGFR as low as approximately 25–30 mL/min/1.73m² with dose adjustment; no eGFR of 60 mL/min/1.73m² threshold for ARNI eligibility appears in current guidelines.
Option E: Option E is incorrect; the 2022 AHA/ACC/HFSA guidelines do not mandate nephrology consultation or a 3-month washout period before initiating RAAS blockade in patients with CKD stage 3; these drugs are routinely initiated by internists, hospitalists, and cardiologists in moderate CKD without specialist clearance.
11. A 58-year-old man of self-identified Black race with HFrEF (LVEF 24%, NYHA class III) remains symptomatic despite sacubitril/valsartan, carvedilol, and eplerenone at maximally tolerated doses. His cardiologist adds hydralazine/isosorbide dinitrate (H/ISDN). Which of the following correctly describes the evidence basis, guideline classification, and clinical role of H/ISDN in this patient?
A) H/ISDN is appropriate here as a substitute for sacubitril/valsartan; the A-HeFT trial demonstrated that H/ISDN provides equivalent mortality reduction to ARNI therapy in self-identified Black patients with HFrEF, and current guidelines permit ARNI-to-H/ISDN substitution to reduce pill burden in patients with NYHA class III symptoms on maximally optimized therapy
B) H/ISDN should not be added in this patient because the A-HeFT trial specifically excluded patients already receiving sacubitril/valsartan or any ARNI; the guideline indication applies only to patients on ACEi or ARB background therapy, and adding H/ISDN to sacubitril/valsartan has no evidence base and risks additive hypotension without demonstrated mortality benefit
C) H/ISDN carries a Class IIb recommendation in self-identified Black patients with HFrEF and NYHA class III–IV symptoms; A-HeFT demonstrated a reduction in HF hospitalization but did not achieve statistical significance for all-cause mortality reduction; the weak recommendation reflects the morbidity-only evidence base
D) H/ISDN carries a Class I recommendation (2022 AHA/ACC/HFSA) as additive therapy in self-identified Black patients with HFrEF who remain symptomatic (NYHA class III–IV) despite optimized ACEi or ARB and beta-blocker; A-HeFT demonstrated a 43% reduction in all-cause mortality and 33% reduction in HF hospitalization with H/ISDN added to standard therapy including background RAAS blockade; H/ISDN is additive to, not a replacement for, RAAS-blocking therapy
E) H/ISDN is indicated as first-line RAAS-replacing therapy in all self-identified Black patients with HFrEF because this population has lower baseline plasma renin activity and derives less hemodynamic benefit from RAAS blockade; H/ISDN's direct vasodilatory mechanism is more effective than RAAS blockade in low-renin HFrEF and should be used instead of ACEi, ARB, or ARNI in this population
ANSWER: D
Rationale:
Option D is correct. The 2022 AHA/ACC/HFSA guidelines give H/ISDN a Class I recommendation as additive therapy in patients of self-identified Black race with HFrEF who remain symptomatic (NYHA class III–IV) despite optimized ACEi or ARB therapy plus a beta-blocker. The evidence basis is the A-HeFT trial, which randomized 1,050 self-identified Black patients with NYHA class III–IV HFrEF to fixed-dose H/ISDN (BiDil) or placebo added to standard HF therapy — which included ACEi or ARB in the majority. The trial was stopped early for overwhelming efficacy: H/ISDN reduced all-cause mortality by 43% and HF hospitalization by 33%. The fundamental clinical principle is that H/ISDN is additive to RAAS blockade — it does not replace ACEi, ARB, or ARNI, and there is no evidence from any trial that H/ISDN produces equivalent or superior mortality benefit to ARNI therapy in any population. In this patient already on sacubitril/valsartan, adding H/ISDN represents a clinically appropriate application of the A-HeFT indication — the background RAAS agent is more potent than ACEi or ARB, but the additive indication based on persistent NYHA III symptoms remains applicable.
Option A: Option A is incorrect; H/ISDN is not equivalent to ARNI therapy in terms of mortality reduction evidence, and guidelines do not permit ARNI-to-H/ISDN substitution to reduce pill burden; the two therapies serve distinct and additive roles.
Option B: Option B is incorrect; while A-HeFT was conducted predominantly in patients on ACEi or ARB background therapy rather than ARNI, the guideline indication based on A-HeFT data extends to patients on ARNI background therapy given the more potent RAAS blockade; there is no guideline statement excluding ARNI-background patients from H/ISDN addition; the Class I recommendation applies to symptomatic patients of self-identified Black race regardless of which RAAS-blocking agent they are receiving.
Option C: Option C is incorrect; H/ISDN carries a Class I (strong) recommendation, not Class IIb; A-HeFT demonstrated a statistically significant reduction in all-cause mortality — 43% — which is the basis for the Class I classification; characterizing the evidence as morbidity-only is factually incorrect.
Option E: Option E is incorrect; H/ISDN is not first-line RAAS-replacing therapy in Black patients with HFrEF; while Black patients on average have lower plasma renin activity, this does not contraindicate RAAS blockade and is not the basis for H/ISDN use; RAAS-blocking therapy (particularly ARNI) carries a Class I recommendation in all eligible HFrEF patients including self-identified Black patients, and H/ISDN is additive to it.
12. A third-year resident is discharging a patient with HFrEF newly started on sacubitril/valsartan 24/26 mg twice daily during hospitalization. She asks the attending what laboratory monitoring is required and when. Which of the following correctly states the guideline-recommended schedule?
A) Renal function and electrolytes should be checked at 24–48 hours after each dose change to detect early hemodynamic renal effects; if creatinine rises more than 10% within 48 hours, the dose should be halved before proceeding to the next titration step
B) Renal function and electrolytes should be checked at 1–2 weeks after initiation, at 1–2 weeks after each dose increase, and at 3 months after reaching the target dose, then at least every 6 months during stable maintenance; RAAS blockers should be temporarily held during intercurrent illness causing volume depletion and restarted after clinical recovery
C) Renal function and electrolytes need only be checked at the 3-month follow-up visit; in-hospital initiation at low starting doses carries negligible renal risk, and post-discharge laboratory monitoring before 3 months is not guideline-endorsed for patients who tolerated the drug without adverse events during hospitalization
D) Renal function and electrolytes should be checked monthly for the first 6 months after initiation regardless of whether the dose is changed, then every 3 months for 1 year, then annually; this fixed schedule is recommended in the 2022 AHA/ACC/HFSA guidelines to detect cumulative renal toxicity from long-term RAAS blockade
E) No fixed monitoring schedule is recommended; the 2022 AHA/ACC/HFSA guidelines endorse symptom-triggered monitoring only, with laboratory tests ordered when the patient reports reduced urine output, leg swelling, or muscle cramps; routine scheduled monitoring in asymptomatic stable patients on RAAS therapy is not endorsed because it increases healthcare utilization without clinical benefit
ANSWER: B
Rationale:
Option B is correct. The guideline-recommended monitoring schedule for renal function and electrolytes after RAAS blocker initiation is: (1) 1–2 weeks after initiation; (2) 1–2 weeks after each dose increase during titration; (3) 3 months after reaching the target dose; (4) at least every 6 months during stable maintenance therapy. This schedule captures the two most clinically significant adverse effects of RAAS blockade — hyperkalemia and creatinine elevation — at the time points when they are most likely to develop: shortly after pharmacodynamic changes and at regular intervals during stable therapy. The sick day rule is an equally important component: volume depletion from any cause dramatically amplifies the risk of AKI in patients on RAAS blockers, and temporary hold during such episodes (gastroenteritis, febrile illness, excessive heat exposure) with restart after recovery is a guideline-endorsed safety practice.
Option A: Option A is incorrect; checking labs at 24–48 hours after each dose change is too early and not the guideline-recommended interval; the maximal hemodynamic renal effect of RAAS blockade manifests over days to 1–2 weeks; a 10% creatinine rise at 48 hours is not a validated threshold for dose reduction.
Option C: Option C is incorrect; delaying the first post-discharge laboratory check to 3 months is inadequate; the 1–2 week monitoring interval after initiation applies regardless of the clinical setting in which the drug was started; early post-discharge labs are particularly important because volume status and renal hemodynamics change substantially after leaving the hospital environment.
Option D: Option D is incorrect; a fixed monthly schedule for 6 months regardless of dose changes is not the guideline-recommended approach; the monitoring interval is tied to pharmacodynamic events (initiation and dose increases), not to a fixed calendar; monthly monitoring of a stable patient on an unchanged dose would over-monitor while under-specifying the timing relative to dose changes.
Option E: Option E is incorrect; scheduled monitoring after RAAS blocker initiation is guideline-recommended; hyperkalemia and creatinine elevation are frequently asymptomatic until clinically significant — relying solely on patient-reported symptoms to trigger laboratory evaluation would miss the majority of early adverse events before they become dangerous.
13. A 57-year-old woman with HFrEF (LVEF 31%, NYHA class II) has been on lisinopril 20 mg daily, carvedilol 25 mg twice daily, and spironolactone 25 mg daily for 14 months. Her BP is 116/72 mmHg, creatinine is stable at 1.0 mg/dL, potassium is 4.3 mEq/L, and she has no history of cough or angioedema. She asks whether her current regimen is optimal. Which of the following best represents the correct RAAS recommendation?
A) She should be transitioned from lisinopril to sacubitril/valsartan; the 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan a Class I recommendation as the preferred RAAS-blocking agent in HFrEF patients with LVEF ≤40% who can tolerate it; she meets all eligibility criteria — hemodynamic stability, adequate renal function, normal potassium, no angioedema history; the transition requires stopping lisinopril, waiting 36 hours, then initiating sacubitril/valsartan 49/51 mg twice daily with titration to 97/103 mg twice daily over 2–4 week intervals as tolerated
B) Her current regimen is fully optimized; lisinopril 20 mg daily exceeds the dose used in PARADIGM-HF (enalapril 10 mg twice daily equivalent) and provides superior ACE inhibition; at doses above the PARADIGM-HF comparator dose, lisinopril provides equivalent or superior outcomes to sacubitril/valsartan, and the transition carries unnecessary risk
C) She should be transitioned from lisinopril to valsartan 160 mg twice daily; the PARADIGM-HF data demonstrate that the valsartan component of sacubitril/valsartan is responsible for the majority of its mortality benefit; standalone high-dose valsartan achieves equivalent outcomes at lower cost and without the angioedema risk associated with neprilysin inhibition by sacubitril
D) Transition to sacubitril/valsartan should be deferred until she develops NYHA class III symptoms; the Class I guideline recommendation applies to NYHA class III–IV patients, and the NNT in the NYHA class II subgroup of PARADIGM-HF was not statistically significant for all-cause mortality reduction
E) Lisinopril should be uptitrated to 40 mg daily and maintained at this maximum dose for at least 6 months; the 2022 AHA/ACC/HFSA guidelines require documentation that the maximum tolerated ACEi dose has been maintained for 6 months before ARNI transition is guideline-compliant, ensuring that incremental ARNI benefit is not attributable to undertreated ACEi dosing
ANSWER: A
Rationale:
Option A is correct. This patient is an ideal candidate for transition from lisinopril to sacubitril/valsartan. The 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan a Class I recommendation (Level of Evidence A) as the preferred RAAS-blocking agent in symptomatic HFrEF (LVEF ≤40%, NYHA class II–IV) for patients who can tolerate it. She meets all eligibility criteria: SBP comfortably above 100 mmHg, stable creatinine, normal potassium, and no angioedema history. PARADIGM-HF directly compared sacubitril/valsartan to enalapril and demonstrated superiority across cardiovascular death, all-cause mortality, HF hospitalization, and sudden cardiac death — remaining on lisinopril when the patient is ARNI-eligible leaves a demonstrated mortality benefit unrealized regardless of the lisinopril dose. The transition protocol is mandatory: stop lisinopril today, wait 36 hours (to allow ACE activity recovery and prevent additive bradykinin accumulation), then initiate sacubitril/valsartan 49/51 mg twice daily, titrating to the target dose of 97/103 mg twice daily over 2–4 week intervals as tolerated.
Option B: Option B is incorrect; there is no dose threshold of ACEi above which lisinopril provides outcomes equivalent to sacubitril/valsartan; PARADIGM-HF directly demonstrated ARNI superiority over enalapril 10 mg twice daily (a standard ACEi dose), and higher ACEi doses do not close this mortality gap; the Class I recommendation for ARNI transition applies regardless of the current ACEi dose.
Option C: Option C is incorrect; the mortality benefit of sacubitril/valsartan demonstrated in PARADIGM-HF arises from the combined neprilysin inhibition plus AT1 blockade — not from the valsartan component alone; transitioning to standalone valsartan does not replicate the ARNI survival benefit and would represent a therapeutic downgrade.
Option D: Option D is incorrect; the Class I recommendation for sacubitril/valsartan in the 2022 guidelines applies to symptomatic HFrEF patients with LVEF ≤40% across NYHA class II–IV; PARADIGM-HF enrolled predominantly NYHA class II–III patients and demonstrated benefit in these classes; deferring transition until class III development unnecessarily delays a mortality-reducing intervention.
Option E: Option E is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require a 6-month period of maximum ACEi dosing before ARNI transition is considered guideline-compliant; the recommendation is to transition ARNI-eligible ACEi-tolerant patients when clinically appropriate; no mandated prior ACEi dose or duration requirement exists before ARNI eligibility.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.